BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22441345)

  • 1. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study.
    Düsing R; Brunel P; Baek I; Baschiera F
    J Hypertens; 2012 May; 30(5):1029-40. PubMed ID: 22441345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose.
    Düsing R; Brunel P; Baek I; Baschiera F
    J Clin Hypertens (Greenwich); 2013 Jan; 15(1):41-7. PubMed ID: 23282123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
    Lacourcière Y; Taddei S; Konis G; Fang H; Severin T; Zhang J
    J Hypertens; 2012 Oct; 30(10):2047-55. PubMed ID: 22828090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study.
    Mancia G; Parati G; Bilo G; Choi J; Kilama MO; Ruilope LM;
    J Hypertens; 2011 Mar; 29(3):600-9. PubMed ID: 21252701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose response and safety of telmisartan in patients with mild to moderate hypertension.
    Smith DH; Matzek KM; Kempthorne-Rawson J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1380-90. PubMed ID: 11185637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy.
    Gil-Extremera B; Ma PT; Yulde J; Kalnins U; Harkin N; Williams L
    Int J Clin Pract; 2003 Dec; 57(10):861-6. PubMed ID: 14712886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension.
    White WB; Littlejohn TW; Majul CR; Oigman W; Olvera R; Seeber M; Schumacher H; Mancia G
    Blood Press Monit; 2010 Aug; 15(4):205-12. PubMed ID: 20613496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained antihypertensive activity of telmisartan compared with valsartan.
    Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
    Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension.
    Nalbantgil I; Nalbantgil S; Ozerkan F; Yilmaz H; Gürgün C; Zoghi M; Aytimur M; Onder R
    Int J Clin Pract Suppl; 2004 Dec; (145):50-4. PubMed ID: 15617460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The Ambulatory Central Aortic Pressure (AmCAP) Study.
    Williams B; Lacy PS; Baschiera F; Brunel P; Düsing R
    Hypertension; 2013 Jun; 61(6):1168-76. PubMed ID: 23630950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of aliskiren 300  mg/hydrochlorothiazide 25  mg (± amlodipine 5  mg) in hypertensive patients not controlled by candesartan 32  mg plus HCT 25  mg.
    Schweizer J; Ulmer HJ; Benduhn H; Klebs S
    Curr Med Res Opin; 2011 Jan; 27(1):131-40. PubMed ID: 21117946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.